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Abstract
AIM: To evaluate the long-term results of conventional 
chemoradiotherapy and laparoscopic mesorectal exci-
sion in rectal adenocarcinoma patients without adju-
vant therapy.
METHODS: Patients with biopsy-proven adenocarci-
noma of the rectum staged cT3-T4 by endoscopic ul-
trasound or magnetic resonance imaging received neo-
adjuvant continuous infusion of 5-fluorouracil for five 
weeks and concomitant radiotherapy. Laparoscopic sur-
gery was planned after 5-8 wk. Patients diagnosed with 
ypT0N0 stage cancer were not treated with adjuvant 
therapy according to the protocol. Patients with ypT1-
2N0 or ypT3-4 or N+ were offered 5-fluorouracil-based 
adjuvant treatment on an individual basis. An external 
cohort was used as a reference for the findings.
RESULTS: One hundred and seventy six patients were 
treated with induction chemoradiotherapy and 170 
underwent total mesorectal excision. Cancer staging 
of ypT0N0 was achieved in 26/170 (15.3%) patients. 
After a median follow-up of 58.3 mo, patients with 
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ypT0N0 had five-year disease-free and overall survival 
rates of 96% (95%CI: 77-99) and 100%, respectively. 
We provide evidence about the natural history of pa-
tients with localized rectal cancer achieving a complete 
response after preoperative chemoradiation. The inher-
ent good prognosis of these patients will have implica-
tions for clinical trial design and care of patients.
CONCLUSION: Withholding adjuvant chemotherapy 
after complete response following standard neoadju-
vant chemoradiotherapy and laparoscopic mesorectal 
excision might be safe within an experienced multidis-
ciplinary team.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This study shows that patients with localized 
rectal cancer can achieve a complete response after 
preoperative chemoradiation. The inherent good prog-
nosis of these patients will have implications for clinical 
trial design and care of patients. Withholding adjuvant 
chemotherapy after complete response following stan-
dard neoadjuvant chemoradiotherapy and laparoscopic 
mesorectal excision might be safe within an experi-
enced multidisciplinary team.
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INTRODUCTION
Randomized clinical trials demonstrate that preoperative 
chemoradiotherapy (CRT) and radiotherapy have better 
local control, lower toxicity and higher compliance than 
postoperative adjuvant CRT for all patients, including 
those selected as high-risk[1,2]. Only one study has shown 
an improvement in disease-free survival (DFS) with the 
preoperative CRT strategy[3]. However, these results 
should be interpreted with caution as the analysis was car-
ried out in only 267 of  the initially planned 900 patients. 
In addition, presurgical CRT was better than presurgical 
radiotherapy alone in terms of  local recurrences in both 
resectable[4-6] and non-resectable patients[7]. No benefit in 
DFS or overall survival (OS) was seen when comparing 
CRT with radiotherapy in resectable tumors. However, 
a significant benefit was obtained in time-to-treatment 
failure and cancer-specific survival, favoring CRT in non-
resectable patients[7].
Although the strategy of  presurgical CRT is well 
established, the benefit of  adjuvant therapy after neoad-
juvant CRT and total mesorectal excision (TME) is not 
supported by randomized clinical trials. Nevertheless, the 
National Comprehensive Cancer Network guidelines rec-
ommended postoperative chemotherapy for all patients 
undergoing preoperative CRT, regardless of  surgical pa-
thology results[8], and the European Society for Medical 
Oncology has recommended a similar strategy for colon 
cancer (high-risk stage Ⅱ and stage Ⅲ)[9]. Interestingly, 
Bujko et al[10] questioned the value of  adjuvant therapy, 
specifically in the subset of  patients that were in remis-
sion. Although patients with complete pathologic remis-
sion (no residual tumor and mesorectal lymph nodes are 
negative for metastases) fare well in multiple series[11,12], 
there is uncertainty as to whether this is due to the induc-
tion (CRT), the adjuvant or to both therapies.
The aim of  this single-institution prospective study 
was to evaluate DFS and OS when adjuvant chemother-
apy was omitted in patients with complete pathologic re-
mission after conventional CRT and laparoscopic TME 
in a tertiary-care setting. An external cohort of  patients 
drawn from a randomized clinical trial[13] was used to 
compare the findings.
MATERIALS AND METHODS
Patients
From November 2000 to November 2008, all patients 
with a biopsy-proven adenocarcinoma of  the rectum 
admitted to the Colorectal Cancer Unit at our hospital 
were evaluated for inclusion in the prospective cohort. 
Exclusion criteria for CRT treatment in the study were: (1) 
early stage (cT1-2N0); (2) cT3Nx located above the line 
crossing the promontorium and the acetabulum in a lat-
eral projection of  the barium enema; (3) elderly patients 
with frailty criteria or over 85 years of  age; (4) patients 
unfit for CRT or with previous pelvic radiotherapy; (5) 
patient refusal to participate; and (6) metastatic disease. 
The study protocol was approved by the Ethics Com-
mittee of  the Hospital Clínic of  Barcelona, Spain.
Preoperative staging and treatment
Staging was performed in all cases by endoscopic ultra-
sound, abdominal spiral computed tomography, barium 
enema, chest X-ray and, after February 2006, pelvic mag-
netic resonance imaging. Patients received neoadjuvant 
chemotherapy comprised of  a continuous infusion of  225 
mg/m2 per day 5-fluorouracil for five weeks, with concur-
rent radiotherapy (45 Gy).
Surgical procedure and pathology evaluation
Surgery was performed by two surgeons (AML and SD 
have both performed approximately 50 laparoscopic rec-
tal surgeries yearly since 1997) and included abdomino-
perineal resection and low anterior resection by laparos-
copy. All resections were performed according to TME 
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principles 5-8 wk after completion of  CRT.
Patients were considered as having achieved a “com-
plete response” if  there was no residual tumor and 
mesorectal lymph nodes were negative for metastases 
(ypT0N0). Hematoxylin and eosin stained specimens 
were reviewed following standard protocols by three 
examiners (JAB, MC, RM) blinded to patient outcome. 
Patients with ypT1-2N0 stage cancer were considered 
as having achieved an “intermediate response”. Patients 
with ypT3-4 specimens or with the presence of  patho-
logic lymph node involvement (ypN1) were considered to 
be “poor responders”.
Postoperative strategy and follow-up
Patients with residual disease (intermediate and non-
responders) were offered adjuvant chemotherapy with 
48 h continuous infusion of  5-fluorouracil (3 g/m2) with 
folinic acid (200 mg/m2) every two weeks for six cycles. 
Patients showing complete pathologic response were not 
offered adjuvant chemotherapy after surgery (“wait and 
see” approach).
Follow-ups consisted of  visits to the surgery and/or 
oncology outpatient clinics every three months during the 
first two years, every six months for the following three 
years, and yearly thereafter. General laboratory work-up 
with carcinoembryonic antigen (CEA) levels was obtained 
and physical examination was performed during all visits. 
Abdominal and pelvic computed tomography scans were 
scheduled every six months for two years and annually 
after the second year of  follow-up. Chest radiograph was 
performed annually and colonoscopy was carried out ev-
ery three years in all patients. When recurrence was sus-
pected, histologic confirmation was attempted whenever 
possible.
External reference
Given that the results of  our single-institution non-random-
ized cohort may reflect a selection of  patients rather than 
the effect of  a therapeutic approach, a second cohort of  
patients following a similar treatment program was taken 
from a randomized clinical trial (NCT01500993) as a ref-
erence to evaluate the results. The NCT01500993 study is 
a non-inferiority clinical trial comparing capecitabine with 
fluorouracil in chemoradiotherapy for locally advanced 
rectal cancer[13]. From this trial, we selected patients 
undergoing the same therapeutic strategy as the main 
cohort: neoadjuvant chemoradiotherapy followed by sur-
gery and adjuvant chemotherapy (both CRT and adjuvant 
chemotherapy could be capecitabine- or fluorouracil-
based), and for whom information was available regard-
ing the degree of  pathologic response achieved after 
chemoradiotherapy. Details on dosing and schedules can 
be found in the main publication[13]. With the exception 
of  two covariates (days in hospital and type of  surgery in 
terms of  open vs laparoscopy), the same information was 
available from this cohort.
Statistical analysis
Statistical analyses were performed using SAS V9.3 soft-
ware (SAS Institute, Cary, NC, United States). Medians 
were compared using a Wilcoxon score test and propor-
tions were compared with a χ 2 test. Logistic regression was 
used to evaluate presurgical determinants for achieving 
a complete response. DFS was defined as the time from 
diagnosis until local and/or distant recurrence or death 
for any cause, whichever occurred first. OS was defined 
as time from diagnosis to death from any cause. Admin-
istrative censoring was established on December 1, 2011. 
Kaplan-Meier curves were used to plot survival and com-
pute five-year DFS and OS. Cox proportional hazards re-
gression with Efron method for ties was used to perform 
the survival analysis. Multivariate analysis was built using 
those variables with a P < 0.10 in the univariate analysis. 
Radial margin involvement was excluded from the multi-
variate analysis given its collinearity with the exposure of  
interest by definition. Continuous variables were entered 
as such in the models. The proportional hazards assump-
tion was verified by plotting the cumulative marginal re-
siduals and assessing for significance.
RESULTS
Patient characteristics and response to CRT
From November 2000 to November 2008, 435 patients 
were evaluated for inclusion. A total of  201 patients 
underwent preoperative CRT. Reasons for exclusion are 
shown in Figure 1. Twenty-five patients were included in 
two clinical trials[14,15] and were not analyzed in the cur-
rent cohort, and six patients did not have radical surgery 
after CRT. Therefore, 170 patients constituted the basis 
of  this analysis. The median age of  all patients was 67 
years (range: 40-85 years) and 68% (116/170) were male 
(Table 1). A fully laparoscopic approach was intended in 
161 (95%) patients, of  whom 17 were switched to open 
surgery (17/161; 4%). A low-anterior resection was per-
formed in 119 (70%) patients and abdominoperineal re-
section was performed in 35 (21%) patients. In the sur-
gical specimens of  81 (48%) patients, 12 or more lymph 
nodes could be identified. The overall median follow-up 
was 58.3 mo (range: 3.8-129.8 mo). Radial margin as-
sessment was carried out in 147 patients (89%). Patients 
with ypT0N0 were considered by definition as R0 inde-
pendently of  radial margin assessment. R0 resection was 
performed in 132/147 (90%) assessed patients. Com-
plete pathologic response was obtained in 15% (26/170) 
of  patients, and an intermediate response was obtained 
in 28% (47/170). A median number of  11 lymph nodes 
were retrieved, and an absence of  lymph node involve-
ment (ypN0) was found in 130/170 specimens (76%).
Significant differences were found in the levels of  
CEA at diagnosis among patients with different types 
of  responses (P < 0.05). There were also significant dif-
ferences among patients with complete, intermediate 
and poor responses in days spent in the hospital and in-
volvement of  the radial margin (negative by definition in 
ypT0N0 patients; Ps < 0.05). Age-, sex-, presurgical stag-
ing- and presurgical hemoglobin-adjusted analyses iden-
tified CEA as the sole predictor of  complete response 
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achievement (used as a continuous variable, OR = 0.82, 
95%CI: 0.68-0.99, P = 0.0362).
DFS and OS
None of  the complete-responder patients received ad-
juvant chemotherapy according to the study protocol, 
though 11/47 (23%) patients with an intermediate re-
sponse did. However, a significantly larger proportion 
(47/97; 48%) of  patients in the poor-responder group 
received adjuvant chemotherapy (P < 0.001).
Recurrences were observed in 46/170 patients (27%). 
In the group of  poor-responders there were 42/97 (43%) 
relapses (30 distant only, 9 local only, and 2 local and dis-
tant relapses). In the group of  intermediate-responders, 
there were two distant relapses and one local relapse (3/47; 
6% relapse). One of  26 (4%) patients with a complete 
response developed metastases and none presented lo-
cal recurrence. The patient with complete response de-
veloped an isolated liver metastasis 15 mo after primary 
resection, which was salvaged with a right hepatectomy. 
Systemic recurrence occurred most frequently in the liver 
(11%), followed by the lung (10%), peritoneum (4%) and 
lymph nodes (3%). Figure 2 shows the cumulative haz-
ards of  local and distant relapse. Local relapses are seen 
late in follow-up in both the intermediate- and poor-re-
sponder groups, which were significantly different among 
groups (P = 0.0112). The cumulative hazard of  distant 
relapse rose steadily in the group of  poor-responders 
and stabilized after 43 mo of  follow-up. Three distant re-
lapses were seen in the group of  intermediate-responders 
in the first 25 mo of  follow-up.
Four patients (4/73; 5%) from the complete- and 
intermediate-responders groups died from causes not 
related to rectal cancer, compared with eight (8/97; 8%) 
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Figure 1  Patient flow chart of the main cohort. CRT: Chemoradiotherapy; CT: Chemotherapy; PE: Pulmonary embolism; RT: Radiotherapy; TEM: Transanal endo-
scopic microsurgery.
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Ineligible for neoadjuvant CRT (n  = 188)
   Stage uT1-2 N0 (n  = 32)
   Anterior resection for upper third location (n  = 33)
   Age > 85 or severe comorbidities (n  = 33)
   Previous pelvic RT for any reason (n  = 5)
   Patient decision (n  = 2)
   No apparent reason (n  = 32)
Rectal cancer cohort (n  = 435)
Stage uT3 NX (n  = 389)
Metastatic disease at diagnosis 
(n  = 46)
Neoadjuvant CRT (n  = 201)
Metastatic disease at 
diagnosis (n  = 176)
Within clinical trials (n  = 25) 
Surgery (n  = 188)
Not operated (n  = 6)
   Unresectable (n  = 2)
   Palliative surgery (n  = 2)
   TEM (n  = 1)
   Death (PD) (n  = 1)
No adjuvant CT (n  = 26)
Poor response (n  = 97)Complete response (n  = 26) Intermediate response 
(n  = 47)
Adjuvant CT (n  = 11) 
No adjuvant CT (n  = 36)
Adjuvant CT (n  = 47)
No adjuvant CT (n  = 50)
Table 1  Descriptive baseline statistics by type of response achieved
patients in the poor-responders group. At a median 
follow-up of  58.3 mo, five-year DFS was 96 (95%CI: 
89-100), 93 (95%CI: 86-100) and 54% (95%CI: 44-65) in 
the complete, intermediate and poor response groups, re-
spectively (P < 0.0001) (Figure 3A). Five-year OS was 100, 
93 (95%CI: 86-100) and 67% (95%CI: 58-78) in the com-
plete, intermediate and poor response groups, respectively 
(P = 0.0002) (Figure 3B).
In the multivariate analysis, type of  response was the 
main predictive factor for DFS. Taking the poor respond-
ers as the reference category (since it is the most frequent 
type of  response), patients with complete response had 
a HR for DFS of  0.07 (95%CI: 0.01-0.54) and patients 
with an intermediate response had an HR of  0.16 (95%CI: 
0.06-0.46). Baseline CEA level and days of  admission 
following surgery were also predictive for DFS (Table 2). 
Patients with intermediate response also presented bet-
ter OS in the multivariate analysis when compared with 
patients with poor response, with an HR of  0.30 (95%CI: 
0.11-0.78) (Table 3).
External reference cohort
One hundred and forty five patients were evaluated from 
the NCT01500993 study. Seventy-three and 72 patients 
were treated with fluorouracil- or capecitabine-based 
regimes, respectively. There were no relevant differences 
from the main cohort in terms of  age, presurgical he-
moglobin, CEA or clinical staging. The proportion of  
patients achieving a complete response was lower in the 
external reference cohort (10%), and the proportion of  
patients with a poor response was slightly higher (62%). 
A multivariate analysis of  age, sex, CEA, clinical stage 
and presurgical hemoglobin did not identify any of  these 
factors as predictors of  response. Of  note, in both co-
horts, clinical stage was unrelated to the type of  response 
achieved (χ 2: P = 0.36 for the main cohort and P = 0.61 
for the external reference cohort).
Three patients did not receive adjuvant chemotherapy, 
one in the complete-responder group and two in the 
poor-responder group. This is the principal difference 
from the main cohort, where complete-responders were 
not treated with adjuvant chemotherapy. Median follow 
up was 43.7 mo (range: 0.5-63.7 mo). No patient with 
complete or intermediate response suffered a local re-
lapse during the study follow-up. Three-year local relapse-
free survival was 90% (87% in the main cohort) (Figure 
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Variable Complete1 Intermediate2 Poor3 P  value
(n  = 26) (n  = 47) (n  = 97)
Age, yr         65.5 (39.9-84.9)          65.7 (42.9-84.0)         65.5 (41.3-83.5)    0.8407
Female 11 (42)  14 (30) 29 (30)    0.4551
CEA4    0.0122
   < 3.6 μg/L 21 (81)  26 (55) 47 (49)
   3.6-20.9 μg/L   5 (19)  20 (43) 41 (42)
   > 20.9 μg/L 0 0 9 (9)
Presurgical hemoglobin, g/dL 13.1 (9.2-16.0)        14.0 (7.9-18.2)       13.4 (7.6-18.4)    0.0580
Clinical stage    0.1325
   cT2N0 0 25 (4) 0 (0)
   cT2N1 0  3 (6) 3 (3)
   cT3N0 11 (42)  21 (45) 38 (39)
   cT3N1 14 (54)  14 (30) 38 (39)
   cT4N0 1 (4)  0 (0) 2 (2)
   cT4N1 0 0 3 (3)
Severe stenosis precluding staging 0    7 (15) 13 (13)
Distance from tumor to anal margin, cm         7.0 (2.0-12.0)          5.0 (1.0-15.0)         8.0 (1.0-15.0)    0.0697
Previous abdominal surgery 14 (54)  16 (34) 39 (40)    0.2546
Type of surgery    0.5368
   APR or miles intervention   4 (15)    8 (17) 23 (24)
   Low-anterior resection 21 (81)  33 (70) 65 (67)
   Other 1 (4)    6 (13) 9 (9)
Laparoscopic vs open surgery    0.1748
   Fully laparoscopic 25 (96)  42 (89) 77 (79)
   Intraoperative conversion to open 1 (4)  4 (9) 12 (12)
   Open from the beginning 0  1 (2) 8 (8)
Hospital stay, d         5.0 (3.0-16.0)    6.5 (4-55)        7 (2-145)    0.0164
Number of lymph nodes resected    11 (1-27)     10 (1-33)    12 (1-29)    0.3768
Patients with ≥ 12 lymph nodes resected 12 (46)  20 (43) 49 (51)    0.6600
Involvement of radial margin < 0.0001
   No   26 (100)  44 (94) 62 (64)
   Yes 0 0 15 (16)
   Not assessed 0  3 (6) 20 (21)
Values are presented as n (%) or median (range), unless otherwise indicated. 1ypT0N0; 2ypT1-2N0; 3ypT3-4N1-2; 4This variable has one missing value; 5Al-
though cT2N0 staging was considered an exclusion criterion, these tumors were located in the low rectum and we considered the risk of local relapse with-
out neoadjuvant chemoradiotherapy too high. APR: Abdominoperineal resection; CEA: Carcinoembryonic antigen. 
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Table 2  Multivariate analysis of disease-free survival
2). Rate of  distant relapse was also different by type of  
response achieved, with a three-year distant relapse-free 
survival of  93%, 84% and 68% for complete-, intermedi-
ate- and poor-responders, respectively (P = 0.0430). In 
the main cohort these percentages are 97%, 96% and 
67% (P < 0.0001).
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Figure 2  Cumulative hazards estimates. A: Local relapse in the main cohort; B: Distant relapse in the main cohort; C: Local relapse in the external reference cohort 
(note: complete- and intermediate-responders overlap); D: Distant relapse in the external reference cohort.
Variable Main cohort External reference cohort
HR (95%CI) P  value HR (95%CI) P  value
Type of response after CRT
   ypT0N0 0.07 (0.01-0.54) 0.0100 0.51 (0.15-1.7) 0.2700
   ypT1-2N0 0.16 (0.06-0.46) 0.0007   0.41 (0.18-0.94) 0.0360
   ypT3-4/N1-2 Reference Reference
CEA 1.02 (1.01-1.03) 0.0010   1.02 (1.01-1.03) 0.0072
Pre-surgery clinical stage
   T2-3N0 Reference Reference
   T4 and/or N1 1.19 (0.82-1.73) 0.3500   1.66 (0.85-3.26) 0.1400
Admission stay after surgery1, d 1.02 (1.01-1.02) 0.0020
1This variable was not available in the external reference cohort. CEA: Carcinoembryonic antigen; CRT: Chemoradiotherapy.
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Table 3  Multivariate analysis of overall survival
The degrees of  response to CRT and CEA level were 
predictors of  DFS (Table 2) and degrees of  response to 
CRT and presurgical clinical stage were predictors of  OS 
(Table 3). There were three deaths in the group of  com-
plete-responders in the external reference cohort. One 
patient died due to distant spread of  the disease, another 
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Figure 3  Kaplan-Meier estimates. A: Disease-free survival in the main cohort; B: Overall survival in the main cohort; C: Disease-free survival in the external refer-
ence cohort; D: Overall survival in the external reference cohort.
A B
C D
Variable Main cohort External reference cohort
HR (95%CI) P  value HR (95%CI) P  value
Chemotherapy1 1.09 (0.55-2.16) 0.810
Type of response after CRT
   ypT0N0 NE 0.61 (0.19-2.02) 0.420
   ypT1-2N0 0.30 (0.11-0.78) 0.014 0.32 (0.13-0.83) 0.019
   ypT3-4/N1-2 Reference Reference
CEA 1.00 (0.97-1.03) 0.780
Presurgical clinical stage
   T2-3N0 Reference
   T4 and/or N1 1.89 (0.95-3.76) 0.069
1This factor was not evaluated in the external reference cohort because all patients were scheduled to receive chemotherapy. CEA: Carcinoembryonic anti-
gen; CRT: Chemoradiotherapy; NE: Not estimable (no deaths). 
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due to myocardial infarction without evidence of  relapse, 
and the third death was due to septic shock following 
elective surgery of  the primary tumor. Three-year OS 
was 86%, 90% and 75% in the complete-, intermediate- 
and poor-responders, respectively (P = 0.0370) (Figure 
3). The magnitude of  the prediction of  OS by degree 
of  response was similar to the main cohort (HR = 0.32, 
95%CI: 0.13-0.83, for intermediate- vs poor-responders) 
(Table 3). The magnitude of  the prediction of  DFS by 
degree of  response, although statistically significant, was 
lower (Table 3). Both DFS and OS were worse by type 
of  response achieved in the external reference cohort 
compared with the main cohort (Figure 3).
DISCUSSION
This is the largest prospective rectal cancer cohort used 
to date to evaluate the withholding of  adjuvant therapy 
for complete pathologic responders after standard CRT 
and laparoscopic resection. Our long-term oncologic re-
sults are comparable with those obtained in our external 
reference cohort and with previous studies[16-18].
We provide evidence that patients achieving ypT0N0 
fare extremely well, despite adjuvant treatment not being 
administered. Complete-responders in the main cohort 
presented even better DFS and OS than those ypT0N0 
patients in the external reference cohort, where adjuvant 
chemotherapy was recommended. Important baseline 
prognostic factors (i.e., age, clinical stage, CEA, hemo-
globin) did not differ between both cohorts. The main 
cohort represents an unselected population, whereas the 
external reference cohort was taken from a clinical trial, 
which tends to include fitter patients.
The most widely used and reproducible system for 
evaluating CRT efficacy is down-staging. Although differ-
ent down-staging classifications have being proposed[18-20], 
the most commonly used method separates ypT0-2N0 
and ypT3-4 or N+. As most patients treated with preop-
erative CRT are staged by endoscopic ultrasound or mag-
netic resonance imaging as cT3, and T3 (involvement of  
mesorectum) is optimally defined with both techniques[21], 
it seems reasonable to use this down-staging classifica-
tion. Another advantage is that this method is widely 
reproducible among pathologists and includes pathologic 
nodal information. Several studies have confirmed the 
prognostic value of  this specific down-staging[16,20,22,23]. 
We observed differences in DFS and OS in the main and 
external reference cohorts. The degree of  pathologic re-
sponse was more discriminative in the main cohort, and 
prognosis was better in each strata. This could be due 
to random variability or to better pathologic assessment 
in the main cohort. Better classification of  the patients 
would encompass a stage migration and improvement of  
the prognosis in every stratum. Other reasons for differ-
ences in the percentage of  complete pathologic responses 
is that time from termination of  CRT and surgery in the 
external reference cohort was usually four weeks, whereas 
in the main cohort it was five to eight weeks.
Although methodologically complex, oncologists should 
pursue the identification of  dynamic strategies of  treat-
ment for rectal cancer where initial response to CRT 
could guide subsequent adjuvant therapies and surveil-
lance policies. This can be achieved either by high-
quality observational data and proper analytic methods[24] 
or with randomized clinical trials. Clinical trials studying 
adjuvant chemotherapy should consider that pathologic 
down-staging after neoadjuvant CRT separates patients 
with different prognoses and endorses proper stratifica-
tion (e.g., ypT1-2N0 vs ypT3-4 or N+). The timing and 
magnitude of  risk of  local and distant recurrence shown 
here may also help to guide postsurgical surveillance 
strategies in these patients. Our results suggest that local 
relapse surveillance can be more flexible in patients with 
good response since the risk is very low.
Adjuvant chemotherapy following neoadjuvant CRT 
has not been proven beneficial in randomized clinical tri-
als[4,25], though an unplanned sub-analysis of  a European 
Organization for Research and Treatment of  Cancer 
Radiation Oncology Group trial suggested a benefit in 
ypT0-2 patients[26]. An important limitation of  this study 
is that only a subset (78%) of  the originally randomized 
patients was included, which introduces the risk of  a se-
lection bias[27] not solved by the original randomization, 
turning the study into an observational one and thus sub-
ject to bias due to unmeasured confounders. Only one 
prospective clinical trial (SCRIPT) is currently evaluating 
the value of  adjuvant therapy with a control arm without 
therapy. The other trial (CHRONICLE) was closed be-
fore schedule due to low accrual.
Although we suggest that patients with ypT0N0 
should not be treated with adjuvant chemotherapy, this 
statement should be taken with caution for two reasons. 
First, the results are based on a single third-level onco-
logic institution, where expert radiologists, surgeons, 
gastroenterologists and oncologists coordinate to provide 
state-of-the art oncologic care and surveillance to pa-
tients, and these results may lack the external validation 
required for extrapolation to other institutions. Second, 
our study has a limited number of  patients. However, 
our study has a long follow-up, is the first to evaluate the 
natural history of  patients after CRT without adjuvant 
therapy, and included all patients with > cT3, mid and 
low rectal tumors younger than 85 years, reflecting a 
non-selected population of  patients.
In conclusion, we have shown that the natural behav-
ior of  ypT0N0 patients is optimal when treated in a ter-
tiary care center and that adjuvant chemotherapy could 
be of  low therapeutic value. Our results suggest that 
withholding adjuvant chemotherapy from those patients 
achieving ypT0N0 after standard neoadjuvant CRT and 
TME, if  treated by an experienced multidisciplinary 
team, might be a reasonable option.
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Background
Preoperative chemoradiation is the standard of care for localized rectal cancer. 
The role of further adjuvant chemotherapy for those patients achieving a com-
plete response is a gray area.
Research frontiers
Current lines of research in rectal cancer aim to tailor treatment to the least in-
vasive approach possible while maintaining the best possible outcomes. Patient 
selection is key in this process. Elements that may help inform patient selec-
tion include genetics, pathway analysis, tumor stage/localization together with 
patients’ comorbidities and overall health status. Evaluation of the response of 
the tumor to therapy as performed in the neoadjuvant setting can act as an ad-
ditional tool for patient selection.
Innovations and breakthroughs
Authors provide evidence about the natural history of patients with localized 
rectal cancer achieving a complete response after preoperative chemoradiation. 
The inherent good prognosis of these patients will have implication on clinical 
trial design and care of patients.
Applications
The results of this study provide evidence for a clinical trial that might consider 
the absence of adjuvant treatment for those patients achieving a pathologically 
complete response after chemoradiation as a control arm. They also provide 
comfort to those patients and physicians that decide upon withholding adjuvant 
chemotherapy in such scenarios.
Terminology
Laparoscopic resection: minimally invasive surgery using small incision in the 
abdomen. Total mesorectal excision: excision of the fat and fascia surrounding 
the rectum along with the rectum itself en bloc. Chemoradiotherapy: combina-
tion of radiotherapy and chemotherapy, which improves local control in rectal 
cancer, when administered preoperatively. Pathologic complete response: ab-
sence of malignant cells in the pathologic specimen after chemoradiotherapy.
Peer review
The manuscript is a retrospective database analysis of rectal cancer patients 
who received neoadjuvant treatment. Those who experienced complete remis-
sion were not given adjuvant treatment and showed a very good outcome. A 
validation cohort is provided. In general, the study is well performed, the manu-
script well written and easy to follow.
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